Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.4151
-0.0135 (-3.15%)
At close: Apr 16, 2026, 4:00 PM EDT
0.409739
-0.0054 (-1.29%)
After-hours: Apr 16, 2026, 7:59 PM EDT
Jaguar Health Revenue
In the year 2025, Jaguar Health had annual revenue of $11.51M, down -1.52%. Jaguar Health had revenue of $3.24M in the quarter ending December 31, 2025, a decrease of -7.81%.
Revenue (ttm)
$11.51M
Revenue Growth
-1.52%
P/S Ratio
0.47
Revenue / Employee
$234,918
Employees
49
Market Cap
5.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.51M | -178.00K | -1.52% |
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
| Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
| Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
| Dec 31, 2015 | 258.38K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| CollPlant Biotechnologies | 2.37M |
| XTL Biopharmaceuticals | 968.00K |
| Bio Green Med Solution | 747.00K |
| Cardio Diagnostics Holdings | 14.83K |
| Ernexa Therapeutics | 1,000.00 |
JAGX News
- 3 days ago - Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs - Accesswire
- 7 days ago - Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates - Accesswire
- 8 days ago - Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 9 days ago - Jaguar Health Reports 2025 Financials - Accesswire
- 14 days ago - Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress - Accesswire
- 4 weeks ago - FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) - Accesswire
- 4 weeks ago - Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression - Accesswire
- 5 weeks ago - Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts - Accesswire